top of page

Who we are...

The Medical Advisory Group (MAG) is an ad hoc committee of experts who were originally charged to examine issues related to the use of aducanumab (Aduhelm™) by persons with Down syndrome. The MAG was organized following the FDA's July 7, 2021 approval of the pharmaceutical firm Biogen's medication, aducanumab, for the treatment of Alzheimer's disease.  The group provides scientific advice to the NTG and is currently focusing on consulting on newly emerging FDA approved Alzheimer's therapeutics.

The ad hoc committee functions under the Clinical Health Care Committee of the NTG, chaired by Seth Keller, MD and Kathryn Service, NPN-BC, in accord with the NTG's Scientific Consultative Panel, chaired by Lucille Esralew, Ph.D.

 

Members of the Advisory Group are drawn from experts across the United States (and other countries) whose work and research with persons with Down syndrome affected by dementia and touches on the many facets of early detection and diagnosis, and interventions, treatments, and health management.  Members are also drawn from health policy, providers, and engaged family members, whose concerns are social care and applicable public policies and support practices.

In 2020, the MAG issued an issues consensus statement on aducanumab and persons with Down syndrome, which can be sourced below.

See also:  Aduhelm & Down Syndrome Information

NTG MAG

MAG Related Publications & Documents

NTG's FAQ on aducanumab and Down syndrome

NTG's FAQ on aducanumab and Down syndrome

Resource document

A comprehensive FAQ issued by the NTG's Medical Advisory Group on questions that were raised about Biogen's new medication for treating Alzheimer's disease still has relevance even though Biogen has withdrawn Aduhelm from production. "We are glad to make this available to families and providers who have questions and concerns about the use of this new medication," said Dr. Seth Keller, the MAG leader.

Aducanumab and Persons with Down Syndrome: What Do We Do Now?

Aducanumab and Persons with Down Syndrome: What Do We Do Now?

Resource document

NTG issued statement on use of Aduhelm by persons with Down syndrome. This statement, the result of a collaborative effort coordinated by the NTG Aduhelm and Down Syndrome Medical Advisory Group, was led by Seth M. Keller, MD, Co-President of the National Task Group on Intellectual Disabilities and Dementia Practices.

bottom of page